NEXGEL (NASDAQ:NXGL) announced that it is developing a brand new eye patch made of hydrogel to treat amblyopia. It is a condition that causes low vision that usually occurs in one eye, but may be seen in both eyes. This condition is also known as lazy eye.
The company, based in Pennsylvania, is called Langhorne. stated that the patch will be available for ophthalmologists and optometrists within the first quarter of 2023.
World’s Leading Window Coverings Norman USA to appear on Designing Spaces
Amblyopia affects the range of 2% to four percent from people in the American population. As per the National Eye Institute in the US It is the most frequent cause of visual impairment in children and affects 2 to 3 children in 100.
The market for amblyopia treatment is predicted to grow to over $6 billion in 2027. Contrary to the current patching method for amblyopia NEXGEL (NASDAQ:NXGL) stated that the hydrogel patch it uses is less irritant for the skin. It is produced without the use of harmful chemical compounds or uncomfortable adhesives.
Dr. Leonard Nelson, co-director of the Pediatric Ophthalmology Department and director of the Strabismus Center at Wills Eye Hospital, said the most effective eye patches to treat amblyopia is to apply them on the cornea’s skin.
“However traditional eye patches for amblyopia can be difficult to alter and remove as they pull at and irritate the thin skin surrounding the eye. Children, the resulting discomfort can result in inadequate compliance and poor treatments,” Nelson said in an announcement.
“NEXGEL (NASDAQ:NXGL)’s innovative hydrogel system is the breakthrough that pediatric eye doctors have been longing for. The patches are soft wearable for long periods without causing discomfort or pain and are easy to remove and replaceable. This is precisely what we require for treating our patients in the pediatric age group,” Nelson said.
NEXGEL (NASDAQ:NXGL) President Adam Levy said being able to rapidly develop the patch after discovering the need for a more effective amblyopia treatment on the market is an attribute of the company’s hydrogel technologies.
“It is another one of its numerous applications in healthcare, especially in the area of contact between medical devices and the skin of a patient,” Levy said in an email.
“Parents as well as doctors have been looking for a better solution to treat this disease for children. we are looking forward to the launch of our product in the early 2023 timeframe,” Levy added.
NEXGEL is a top supplier of hydrogels that are ultra-gentle and high-water content products for both consumer and healthcare applications.
